HRP20140214T1 - Derivati tetrahidrokinolina za lijeäśenje posttraumatskog stresnog poremeä†aja - Google Patents
Derivati tetrahidrokinolina za lijeäśenje posttraumatskog stresnog poremeä†aja Download PDFInfo
- Publication number
- HRP20140214T1 HRP20140214T1 HRP20140214AT HRP20140214T HRP20140214T1 HR P20140214 T1 HRP20140214 T1 HR P20140214T1 HR P20140214A T HRP20140214A T HR P20140214AT HR P20140214 T HRP20140214 T HR P20140214T HR P20140214 T1 HRP20140214 T1 HR P20140214T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- acceptable salt
- use according
- Prior art date
Links
- 208000028173 post-traumatic stress disease Diseases 0.000 title claims 3
- 125000000147 tetrahydroquinolinyl group Chemical class N1(CCCC2=CC=CC=C12)* 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- BYGBTDRDPBJUBB-LHIMUUITSA-N (2r)-2-[(1s)-6,7-dimethoxy-1-[2-[4-(trifluoromethyl)phenyl]ethyl]-3,4-dihydro-1h-isoquinolin-2-yl]-n-methyl-2-phenylacetamide;hydrochloride Chemical compound Cl.C([C@H]1C2=CC(OC)=C(OC)C=C2CCN1[C@@H](C(=O)NC)C=1C=CC=CC=1)CC1=CC=C(C(F)(F)F)C=C1 BYGBTDRDPBJUBB-LHIMUUITSA-N 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- -1 2-(4-trifluoromethyl-phenyl)-ethyl Chemical group 0.000 claims 1
- DKMACHNQISHMDN-RPLLCQBOSA-N Almorexant Chemical group C([C@H]1C2=CC(OC)=C(OC)C=C2CCN1[C@@H](C(=O)NC)C=1C=CC=CC=1)CC1=CC=C(C(F)(F)F)C=C1 DKMACHNQISHMDN-RPLLCQBOSA-N 0.000 claims 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Claims (10)
1. Uporaba spoja formule Ia
[image]
naznačena time, da
svaki od R1 i R2predstavlja neovisno (C1-C4)alkoksi,
R3 predstavlja aril-(C1-C4)alkil ili heteroaril-(C1-C4)alkil, i
R4 predstavlja (C1-C3)alkil,
ili farmaceutski prihvatljiva sol toga spoja formule Ia koji se koristi u proizvodnji lijeka za prevenciju ili liječenje posttraumatskog stresnog poremećaja.
2. Uporaba prema zahtjevu 1, naznačena time, da je spoj formule Iaili njegova farmaceutski prihvatljiva sol takav/takva da R1 predstavlja metoksi ili etoksi.
3. Uporaba prema zahtjevu 1 ili 2, naznačena time, da je spoj formule Iaili njegova farmaceutski prihvatljiva sol takav/takva da R2 predstavlja metoksi ili etoksi.
4. Uporaba prema jednom od zahtjeva 1 do 3, naznačena time, da je spoj formule Iaili njegova farmaceutski prihvatljiva sol takav/takva da R3 predstavlja aril-(C1-C4)alkil.
5. Uporaba prema zahtjevu 4, naznačena time, da je spoj formule Iaili njegova farmaceutski prihvatljiva sol takav/takva da R3 predstavlja 2-(4-trifluorometil-fenil)-etil.
6. Uporaba prema jednom od zahtjeva 1 do 3, naznačena time, da je spoj formule Iaili njegova farmaceutski prihvatljiva sol takav/takva da R3 predstavlja heteroaril-(C1-C4)alkil.
7. Uporaba prema jednom od zahtjeva 1 do 6, naznačena time, da je spoj formule Iaili njegova farmaceutski prihvatljiva sol takav/takva da R4 predstavlja metil.
8. Uporaba prema zahtjevu 1, naznačena time, da spoj formule Iaili njegova farmaceutski prihvatljiva sol je (R)-2-{(S)-6,7-dimetoksi-1-[2-(4-trifluorometil-fenil)-etil]-3,4-dihidro-1H-izokinolin-2-il}-N-metil-2-fenil-acetamid ili jedna od njegovih farmaceutski prihvatljivih soli.
9. Uporaba prema zahtjevu 8, naznačena time, da se koristi (R)-2-{(S)-6,7-dimetoksi-1-[2-(4-trifluorometil-fenil)-etil]-3,4-dihidro-1H-izokinolin-2-il}-N-metil-2-fenil-acetamid-hidroklorid.
10. Spoj formule Iaopisan prema jednom od zahtjeva 1 do 9, ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da se upotrebljava u prevenciji ili liječenju posttraumatskog stresnog poremećaja.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2007054130 | 2007-10-10 | ||
| PCT/IB2008/054138 WO2009047723A2 (en) | 2007-10-10 | 2008-10-09 | Tetrahydroquinoline derivatives for treating post-traumatic stress disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140214T1 true HRP20140214T1 (hr) | 2014-04-11 |
Family
ID=40467356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140214AT HRP20140214T1 (hr) | 2007-10-10 | 2014-03-10 | Derivati tetrahidrokinolina za lijeäśenje posttraumatskog stresnog poremeä†aja |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9532985B2 (hr) |
| EP (1) | EP2207550B1 (hr) |
| JP (1) | JP5883222B2 (hr) |
| KR (1) | KR101733247B1 (hr) |
| CN (1) | CN101820878B (hr) |
| AR (1) | AR068768A1 (hr) |
| AU (1) | AU2008309194B2 (hr) |
| BR (1) | BRPI0818617A2 (hr) |
| CA (1) | CA2699504C (hr) |
| CY (1) | CY1114799T1 (hr) |
| DK (1) | DK2207550T3 (hr) |
| EA (1) | EA017443B1 (hr) |
| ES (1) | ES2444418T3 (hr) |
| HK (1) | HK1145440A1 (hr) |
| HR (1) | HRP20140214T1 (hr) |
| IL (1) | IL204838A (hr) |
| MA (1) | MA31800B1 (hr) |
| MX (1) | MX2010003711A (hr) |
| MY (1) | MY153044A (hr) |
| NZ (1) | NZ585086A (hr) |
| PE (1) | PE20091010A1 (hr) |
| PL (1) | PL2207550T3 (hr) |
| PT (1) | PT2207550E (hr) |
| SI (1) | SI2207550T1 (hr) |
| TW (1) | TWI428129B (hr) |
| UA (1) | UA99150C2 (hr) |
| WO (1) | WO2009047723A2 (hr) |
| ZA (1) | ZA201003251B (hr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2669561A1 (en) | 2006-12-22 | 2008-07-03 | Actelion Pharmaceuticals Ltd | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine derivatives |
| EP2307417A2 (en) | 2008-06-25 | 2011-04-13 | Actelion Pharmaceuticals Ltd. | 5,6,7,8-tetrahydro-imidazo[1,5-a]pyrazine compounds |
| EP2402322A1 (en) | 2010-07-02 | 2012-01-04 | Actelion Pharmaceuticals Ltd. | 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist |
| KR101802726B1 (ko) | 2010-08-24 | 2017-11-29 | 액테리온 파마슈티칼 리미티드 | 오렉신 수용체 안타고니스트로서의 프롤린 술폰아미드 유도체 |
| TWI516484B (zh) | 2010-09-22 | 2016-01-11 | 衛材Ｒ＆Ｄ企管股份有限公司 | 環丙烷化合物 |
| JP5847830B2 (ja) | 2010-11-10 | 2016-01-27 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | オレキシン受容体拮抗薬として有用なラクタム誘導体 |
| WO2012085852A1 (en) | 2010-12-22 | 2012-06-28 | Actelion Pharmaceuticals Ltd | 3,8-diaza-bicyclo[4.2.0]oct-8-yl amides |
| EP2675801B1 (en) | 2011-02-18 | 2015-04-08 | Actelion Pharmaceuticals Ltd. | Novel pyrazole and imidazole derivatives useful as orexin antagonists |
| WO2012114252A1 (en) | 2011-02-21 | 2012-08-30 | Actelion Pharmaceuticals Ltd | Novel indole and pyrrolopyridine amides |
| WO2013050938A1 (en) | 2011-10-04 | 2013-04-11 | Actelion Pharmaceuticals Ltd | 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives |
| SI2776430T1 (sl) | 2011-11-08 | 2016-06-30 | Actelion Pharmaceuticals Ltd. | 2-(1,2,3-triazol-2-il)benzamidni in 3-(1,2,3-triazol-2-il)pikolinamidni derivati kot antagonisti oreksinskega receptorja |
| LT2855453T (lt) | 2012-06-04 | 2017-02-27 | Actelion Pharmaceuticals Ltd. | Benzimidazolo prolino dariniai |
| KR102151288B1 (ko) | 2012-10-10 | 2020-09-03 | 이도르시아 파마슈티컬스 리미티드 | [오르토 바이 (헤테로 )아릴]-[2-(메타 바이 (헤테로 )아릴)-피롤리딘-1-일]-메타논 유도체인 오렉신 수용체 안타고니스트 |
| CN105051040A (zh) | 2013-03-12 | 2015-11-11 | 埃科特莱茵药品有限公司 | 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物 |
| NO3077389T3 (hr) | 2013-12-03 | 2018-02-10 | ||
| UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
| PL3077391T3 (pl) | 2013-12-04 | 2019-01-31 | Idorsia Pharmaceuticals Ltd | Zastosowanie pochodnych benzimidazoloproliny |
| JP6659681B2 (ja) | 2014-10-23 | 2020-03-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 不眠症を治療するための組成物および方法 |
| JP7179049B2 (ja) * | 2017-08-01 | 2022-11-28 | ベルゲン ファーマシューティカル、 エルエルシー | オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途 |
| WO2020007964A1 (en) | 2018-07-05 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives |
| WO2020007977A1 (en) | 2018-07-06 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 7-trifluoromethyl-[1,4]diazepan derivatives |
| WO2020099511A1 (en) | 2018-11-14 | 2020-05-22 | Idorsia Pharmaceuticals Ltd | Benzimidazole-2-methyl-morpholine derivatives |
| WO2023218023A1 (en) | 2022-05-13 | 2023-11-16 | Idorsia Pharmaceuticals Ltd | Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA02008797A (es) * | 2000-03-14 | 2005-09-08 | Actelion Pharmaceuticals Ltd | Derivados de 1,2,3,4-tetrahidroisoquinolina. |
| KR20050114242A (ko) | 2003-03-26 | 2005-12-05 | 액테리온 파마슈티칼 리미티드 | 오렉신 수용체 길항제로서 이용되는테트라하이드로이소퀴놀릴 아세트아마이드 유도체 |
| EP1751111B1 (en) | 2004-03-01 | 2014-12-31 | Actelion Pharmaceuticals Ltd. | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives |
| US7501395B2 (en) * | 2005-04-25 | 2009-03-10 | Eisai R & D Management Co., Ltd. | Method of screening for antianxiety drugs |
| KR101065239B1 (ko) * | 2006-03-15 | 2011-09-16 | 액테리온 파마슈티칼 리미티드 | 기억 기능을 증진하는 테트라히드로이소퀴놀린 유도체 |
| EP2402322A1 (en) | 2010-07-02 | 2012-01-04 | Actelion Pharmaceuticals Ltd. | 1,2,3,4-tetrahydroisoquinoline derivative and its use as orexin receptor antagonist |
-
2008
- 2008-10-07 PE PE2008001739A patent/PE20091010A1/es not_active Application Discontinuation
- 2008-10-09 JP JP2010528515A patent/JP5883222B2/ja active Active
- 2008-10-09 AU AU2008309194A patent/AU2008309194B2/en not_active Ceased
- 2008-10-09 PL PL08807937T patent/PL2207550T3/pl unknown
- 2008-10-09 PT PT88079371T patent/PT2207550E/pt unknown
- 2008-10-09 EA EA201000557A patent/EA017443B1/ru not_active IP Right Cessation
- 2008-10-09 MY MYPI2010001561A patent/MY153044A/en unknown
- 2008-10-09 MX MX2010003711A patent/MX2010003711A/es active IP Right Grant
- 2008-10-09 SI SI200831152T patent/SI2207550T1/sl unknown
- 2008-10-09 CN CN2008801113334A patent/CN101820878B/zh active Active
- 2008-10-09 CA CA2699504A patent/CA2699504C/en active Active
- 2008-10-09 US US12/681,802 patent/US9532985B2/en active Active
- 2008-10-09 KR KR1020107010186A patent/KR101733247B1/ko active IP Right Grant
- 2008-10-09 NZ NZ585086A patent/NZ585086A/en unknown
- 2008-10-09 WO PCT/IB2008/054138 patent/WO2009047723A2/en active Application Filing
- 2008-10-09 AR ARP080104422A patent/AR068768A1/es unknown
- 2008-10-09 BR BRPI0818617-0A patent/BRPI0818617A2/pt not_active Application Discontinuation
- 2008-10-09 TW TW097139093A patent/TWI428129B/zh active
- 2008-10-09 EP EP08807937.1A patent/EP2207550B1/en active Active
- 2008-10-09 UA UAA201005122A patent/UA99150C2/ru unknown
- 2008-10-09 ES ES08807937.1T patent/ES2444418T3/es active Active
- 2008-10-09 DK DK08807937.1T patent/DK2207550T3/da active
-
2010
- 2010-04-06 IL IL204838A patent/IL204838A/en active IP Right Grant
- 2010-04-30 MA MA32806A patent/MA31800B1/fr unknown
- 2010-05-07 ZA ZA2010/03251A patent/ZA201003251B/en unknown
- 2010-12-17 HK HK10111852.2A patent/HK1145440A1/xx not_active IP Right Cessation
-
2014
- 2014-02-04 CY CY20141100085T patent/CY1114799T1/el unknown
- 2014-03-10 HR HRP20140214AT patent/HRP20140214T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140214T1 (hr) | Derivati tetrahidrokinolina za lijeäśenje posttraumatskog stresnog poremeä†aja | |
| JP2011500550A5 (hr) | ||
| HRP20171028T1 (hr) | Indolski i indazolski spojevi koji aktiviraju ampk | |
| HRP20200274T1 (hr) | Terapeutski aktivni spojevi i postupci njihove uporabe | |
| HRP20171197T1 (hr) | Bifenilsulfonamidni antagonist receptora endotelina i angiotensina ii, namijenjen liječenju glomeruloskleroze | |
| HRP20130846T1 (hr) | Derivati indolizina i njihova uporaba u medicinske svrhe | |
| HRP20140501T1 (hr) | Derivati benzazepina korisni kao antagonisti vazopresina | |
| HRP20161657T1 (hr) | Kinazolinoni kao inhibitori humane fosfatidilinozitol 3- kinaze delta | |
| HRP20130976T1 (hr) | Karbonilaminopirolopirazoli, potentni inhibitori kinaza | |
| HRP20100553T1 (hr) | Inhibitori replikacije virusa humane imunodeficijencije | |
| HRP20150119T1 (hr) | N-supstituirani derivati glicina kao inhibitori hidroksilaze | |
| PH12020550921A1 (en) | Cap-dependent endonuclease inhibitors | |
| HRP20170873T1 (hr) | Monociklički derivat piridina | |
| BRPI1006766B8 (pt) | sais de meglumina, trometamina e arginina de um inibidor de dihidroorotato dehidrogenase, composição farmacêutica e uso dos mesmos | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| WO2008042240A3 (en) | Enantiomerically pure phosphoindoles as hiv inhibitors | |
| ATE463483T1 (de) | 6-substituierte isochinolinderivate als rock-1- inhibitoren | |
| GEP20186839B (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| AR071222A1 (es) | Compuestos heterociclicos espirocondensados | |
| NZ612544A (en) | Heterocyclic compounds suitable for the treatment of dyslipidemia | |
| DOP2012000053A (es) | Derivados de (tio) morfolina como moduladores de s1p | |
| ECSP099767A (es) | Derivados de n' - (fenil) -n- (morfolin-4-il-piridin-2-il) -pirimidina-2, 4-diamina como inhibidores de quinasas ephb4 para el tratamiento de afecciones proliferativas | |
| JP2014510055A5 (hr) | ||
| HRP20171786T1 (hr) | Heterociklični amidni spoj octene kiseline | |
| HRP20192275T1 (hr) | Novi spojevi 3,4-dihidro-2h-izokinolin-1-ona i 2,3-dihidro-izoindol-1-ona |